Shareholder update

EKF Diagnostics Holdings plc, the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that the Board of Directors have initiated a strategic review.

An independent committee of the Non-Executive Directors will lead the strategic review, chaired by Dr Kevin Wilson and consisting of Adam Reynolds, David Toohey and Doris Ann Williams.

The independent committee are committed to completing their review as soon as practicable.

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Confirmation of share cancellation - Total voting rights

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 (the "Previous Announcement") and confirms that with effect from 22 December 2017 it will cancel 78,113 of the 205,561 Compensation Shares (as defined in the Previous Announcement (the "Cancellation").

Total voting rights

As at 30 November 2017, the Company's total issued share capital consists of 457,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.

TR-1: Standard form for notification of major holdings

Standard form for notification of major holdings

Confirmation of share cancellation

EKF Diagnostics Holdings plc confirms that the 6,630,032 will be cancelled.

Total voting rights

As at 31 October 2017, the Company's total issued share capital consists of 458,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds 1,000,000 Ordinary Shares in treasury.